Peptide index

Experimental pro-apoptotic peptidomimetic that kills the blood supply feeding white adipose tissue - it works in animals and it damaged their kidneys doing it.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Albumin-fused weekly GLP-1 agonist that was withdrawn commercially in 2018 despite a positive cardiovascular outcomes trial - historically important, practically extinct.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Single-molecule GLP-1 and amylin co-agonist from Novo Nordisk with the steepest early weight-loss curve reported to date - about 22% in 36 weeks in a phase 1b/2a study.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Chinese-approved full-length recombinant human GLP-1, identical to the natural hormone and therefore dosed three times daily before meals.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

A 12-amino-acid peptide found by AI screening at Stanford that suppresses appetite through hypothalamic POMC neurons without nausea - impressive in mice and pigs, untested in humans.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Weekly amylin and calcitonin receptor agonist that produces satiety through a completely separate pathway from GLP-1 and appears to preserve lean mass better than incretins alone.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Fixed-dose weekly combination of the amylin analogue cagrilintide with semaglutide, giving about 20% weight loss by hitting two independent satiety pathways at once.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

AstraZeneca's daily GLP-1 and glucagon dual agonist, studied mainly in diabetic kidney disease and liver disease and now largely deprioritised.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Pfizer's oral small-molecule GLP-1 agonist, discontinued after a liver-injury signal - the cautionary reference compound for the whole oral incretin class.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Zealand's GLP-1 and GLP-2 dual agonist, unusual in the class for targeting gut barrier integrity and inflammation alongside weight.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Weekly GLP-1-Fc fusion protein used mainly for type 2 diabetes, with good glycaemic control but only modest weight effects.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

cAMP-biased long-acting GLP-1 analogue newly approved in China for weight management, delivering about 13% placebo-adjusted weight loss at 2.4 mg weekly.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

GLP-1 and glucagon dual agonist being developed by Merck primarily as a liver drug, after producing a roughly 73% reduction in liver fat over 24 weeks.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Long-acting exendin-based GLP-1 agonist notable for the AMPLITUDE-O trial, which showed cardiovascular and kidney benefit in a high-risk diabetic population.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Eli Lilly's selective amylin receptor agonist, which produced roughly 20% weight loss in phase 2 with a strikingly clean gastrointestinal profile.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Gila-monster-venom-derived GLP-1 mimetic - the original incretin drug, and still the reference exendin scaffold that most long-acting analogues are built on.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

The counter-regulatory pancreatic hormone used as rescue therapy for severe hypoglycaemia, and the parent scaffold for every glucagon-arm dual and triple agonist.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

The archetypal therapeutic peptide hormone family, spanning rapid-acting mealtime analogues through to once-weekly basal insulin icodec.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

First-generation daily GLP-1 agonist that produces around 8% weight loss - largely superseded by weekly drugs but now cheap and available generically.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Short-acting prandial GLP-1 agonist built to crush postprandial glucose spikes rather than to produce weight loss.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Monthly antibody-peptide conjugate that pairs GLP-1 agonism with GIP receptor antagonism, notable for how slowly weight comes back after dosing stops.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Oxyntomodulin-based GLP-1 and glucagon dual agonist approved in China, notable for adding thermogenic energy expenditure to appetite suppression.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

The first non-peptide oral GLP-1 agonist approved for obesity - a real tablet with no food or water restrictions, giving about 12% weight loss at the top dose.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

The endogenous proglucagon-derived dual GLP-1 and glucagon agonist that inspired the entire dual-agonist drug class.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Altimmune's balanced 1:1 GLP-1 and glucagon dual agonist, positioned specifically for lean-mass-sparing weight loss and MASH rather than maximum scale-weight reduction.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Ileal satiety hormone acting on Y2 receptors, explored intranasally and as an adjunct to GLP-1 therapy but repeatedly defeated by nausea.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Once-weekly amylin analogue from Zealand and Roche aiming for double-digit weight loss with essentially placebo-level nausea, now heading into phase 3.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

FDA-approved synthetic amylin analogue taken with mealtime insulin to flatten postprandial glucose and reduce food intake - the only approved amylin drug there is.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Triple agonist at the GIP, GLP-1 and glucagon receptors that added glucagon-driven energy expenditure to appetite suppression and produced up to 30% weight loss in phase 3.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Long-acting GLP-1 receptor agonist that slows gastric emptying and blunts appetite, producing roughly 15% body-weight loss at 2.4 mg weekly.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Melanocortin-4 receptor agonist approved for rare genetic and acquired hypothalamic obesity - it works spectacularly in the right genotype and does very little in ordinary obesity.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Boehringer and Zealand's weekly glucagon and GLP-1 dual agonist, giving about 16.6% weight loss in phase 3 alongside some of the strongest liver-fibrosis data in the class.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Triple noradrenaline, dopamine and serotonin reuptake inhibitor used off-label for appetite suppression - not a peptide, but ubiquitous in peptide-adjacent weight protocols.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Dual GIP and GLP-1 receptor agonist delivering around 21% mean weight loss at 15 mg weekly - currently the most effective approved obesity drug on the market.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)

Viking Therapeutics' GLP-1 and GIP dual agonist, with both a weekly injection and a daily tablet in late-stage trials and unusually fast early weight loss.

Incretin & Metabolic (GLP-1 / GIP / Glucagon / Amylin)